Kaken Pharmaceutical Co (TSE:4521) Enterprise Value: 円100,831 Mil (As of Jul. 21, 2026) ***

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4521 Kaken Pharmaceutical Co Ltd TSE:4521
69 GF Score
Price 円3,900.00
GF Value 円3,775.44
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Kaken Pharmaceutical Co Enterprise Value?

Kaken Pharmaceutical Co TSE:4521 +1.04% 69 Enterprise Value is 円100,831 Mil as of Jul. 21, 2026. GuruFocus rates TSE:4521 with a GF Score™ of 69/100 and a GF Value™ of 円3,775.44 (Fairly Valued). The stock has 2 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kaken Pharmaceutical Co's Enterprise Value is 円100,831 Mil. Kaken Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円2,358 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-EBIT ratio for today is 42.76.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kaken Pharmaceutical Co's Enterprise Value is 円100,831 Mil. Kaken Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円5,683 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-EBITDA ratio for today is 17.74.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Kaken Pharmaceutical Co's Enterprise Value is 円100,831 Mil. Kaken Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円76,871 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-Revenue ratio for today is 1.31.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Kaken Pharmaceutical Co's Enterprise Value is 円100,831 Mil. Kaken Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-OCF ratio for today is .

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Kaken Pharmaceutical Co's Enterprise Value is 円100,831 Mil. Kaken Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-FCF ratio for today is .

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Kaken Pharmaceutical Co  (TSE:4521) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Kaken Pharmaceutical Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=100831.429/2358
=42.76

Kaken Pharmaceutical Co's current Enterprise Value is 円100,831 Mil.
Kaken Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,358 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Kaken Pharmaceutical Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=100831.429/5683
=17.74

Kaken Pharmaceutical Co's current Enterprise Value is 円100,831 Mil.
Kaken Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円5,683 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Kaken Pharmaceutical Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=100831.429/76871
=1.31

Kaken Pharmaceutical Co's current Enterprise Value is 円100,831 Mil.
Kaken Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円76,871 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Kaken Pharmaceutical Co's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=100831.429/0
=

Kaken Pharmaceutical Co's current Enterprise Value is 円100,831 Mil.
Kaken Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Kaken Pharmaceutical Co's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=100831.429/0
=

Kaken Pharmaceutical Co's current Enterprise Value is 円100,831 Mil.
Kaken Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaken Pharmaceutical Co Enterprise Value Related Terms


Kaken Pharmaceutical Co Enterprise Value Historical Data

* Premium members only.

The historical data trend for Kaken Pharmaceutical Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co Enterprise Value Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76,916.02 68,630.74 69,404.72 105,853.32 109,918.52

Kaken Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105,853.32 93,091.30 85,077.80 110,052.02 109,918.52

TSE:4521 vs ZTS, UTHR: Enterprise Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co Enterprise Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Enterprise Value falls into.


TSE:4521
69GF Score
Kaken Pharmaceutical Co Ltd TSE:4521
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kaken Pharmaceutical Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Kaken Pharmaceutical Co's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as

Kaken Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of 円100,831 Mil mean?
Kaken Pharmaceutical Co (TSE:4521) has a Enterprise Value of 円100,831 Mil as of Jul. 21, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Enterprise Value too high?
Kaken Pharmaceutical Co's current Enterprise Value is 円100,831 Mil. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Enterprise Value compare to ZTS and UTHR?
Kaken Pharmaceutical Co's Enterprise Value of 円100,831 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Enterprise Value is 円100,831 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,775.44, compared to a current price of 円3,900.00 — trading 3.3% above its estimated fair value. The current Enterprise Value is 円100,831 Mil. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current Enterprise Value is 円100,831 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?

Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,900.00 is trading 3.3% above its estimated GF Value™ of 円3,775.44. GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4521:

  • Enterprise Value: 円100,831 Mil
  • GF Value™: 円3,775.44 vs. price of 円3,900.00 (3.3% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kaken Pharmaceutical Co Business Description

Address 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score

Get the complete analysis for TSE:4521

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,900.00
Price
円3,775.44
GF Value